Filing Flows › Vistagen Therapeutics (VTGN) › Q3 FY26
Vistagen Therapeutics (VTGN) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Feb 12, 2026
Vistagen Therapeutics (VTGN) reported revenue of $303K for the third quarter fiscal 2026 (Q3 FY26), +29% from a year earlier and +17% from the quarter before.
Vistagen Therapeutics, Q3 FY26: revenue $303K (+30% year over year), net loss $18.9M, operating cash flow −$17.6M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $303K | +17% | +29% |
| Operating profit | −$19.5M | — | — |
| Net earnings | −$18.9M | — | — |
| Operating cash flow | −$17.6M | — | — |
What changed
Revenue was $303K in Q3 FY26, up 29% year over year and up 17% from the previous quarter.
Operating costs exceeded revenue by $19.5M, an operating margin of -6450.8%. Total costs grew 29% against revenue growth of 29%. The fastest-growing cost line was General & admin (+39%). The quarter ended with a net loss of $18.9M, narrower than the previous quarter's $19.4M loss.
Operating cash flow was −$17.6M. Non-cash charges added back $54K of depreciation and amortization and $1.1M of share-based compensation. Capital expenditures of $26K exceeded it, leaving free cash flow of −$17.7M.
Questions
What was Vistagen Therapeutics' revenue in the third quarter fiscal 2026?
Vistagen Therapeutics (VTGN) reported revenue of $303K for the third quarter fiscal 2026 (Q3 FY26), +29% from a year earlier and +17% from the quarter before.